Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

NCT ID: NCT01176968

Last Updated: 2020-12-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1012 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Administration of eplerenone within 24 hours of onset of symptoms of myocardial infarction, in patients without heart failure, reduces cardiovascular mortality / morbidity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Eplerenone plus standard of care

Group Type EXPERIMENTAL

Eplerenone

Intervention Type DRUG

Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.

Placebo plus standard of care

Matching placebo for eplerenone 25mg film coated tablets.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Eplerenone

Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.

Intervention Type DRUG

Placebo

Matching placebo tablets

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Inspra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must have experienced a myocardial infarction (STEMI) within the previous 24 hours confirmed by symptoms and ECG.

Exclusion Criteria

* Subjects with a known low ejection fraction of less than 40% or any previous history of heart failure.
* Subjects treated with eplerenone or other aldosterone antagonists within the past 1 month.
* The subject has uncontrolled hypotension (SBP\<90mmHg).
* Subjects with eGFR ≤30ml/min (based on admission serum creatinine and the MDRD formula) or serum creatinine ≥220µmol/L.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alberta Hospital

Edmonton, Alberta, Canada

Site Status

Walter C Mackenzie Health Sciences Centre (WCM)

Edmonton, Alberta, Canada

Site Status

Diamond Health Care Centre (DHCC)

Vancouver, British Columbia, Canada

Site Status

Vancouver General Hospital - Centennial Pavilion

Vancouver, British Columbia, Canada

Site Status

Vancouver General Hospital, Vancouver Coastal Health Authority

Vancouver, British Columbia, Canada

Site Status

Health Sciences Center, Eastern Health

St. John's, Newfoundland and Labrador, Canada

Site Status

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Site Status

St. Michael's Hospital

Toronto, Ontario, Canada

Site Status

Centre de Sante et de Services Sociaux de Chicoutimi (CSSSC) (Complexe Hospitalier de la Sagamie)

Chicoutimi, Quebec, Canada

Site Status

ECOGENE-21 / Centre de sante et de services sociaux de Chicoutimi

Chicoutimi, Quebec, Canada

Site Status

Centre Hospitalier Universitaire de Sherbrooke, Hopital Fleurimont

Sherbrooke, Quebec, Canada

Site Status

Fakultni nemocnice Brno

Brno, , Czechia

Site Status

Fakultni nemocnice Hradec Kralove

Hradec Králové, , Czechia

Site Status

Fakultni nemocnice Hradec Kralove

Hradec Králové, , Czechia

Site Status

I.Interni klinika-kardiologie FN Olomouc

Olomouc, , Czechia

Site Status

I. Interni klinika - kardiologie FN Olomouc

Olomouc, , Czechia

Site Status

Klinika kardiologie IKEM

Prague, , Czechia

Site Status

Nemocnice Na Homolce - kardiologicke oddeleni

Prague, , Czechia

Site Status

Chu Rangueil Service de Cardiologie, A - Bat H1

Toulouse, Cedex 4, France

Site Status

Chu du Bocage - Centre de Cardiologie

Dijon, Cedex, France

Site Status

Hopital De La Pitie Salpetriere

Paris, Cedex, France

Site Status

Service Cardiologie, Centre Hospitalier de Cannes

Cannes, , France

Site Status

Hôpital Henri Mondor - Pysiologie explorations fonctionnelles

Créteil, , France

Site Status

Hôpital Henri Mondor

Créteil, , France

Site Status

Centre de Cardiologie d'Evecquemont

Évecquemont, , France

Site Status

Service Cardiologie Hopital Robert Boulin

Libourne, , France

Site Status

Cardiologie Interventionnelle

Pessac, , France

Site Status

Universitaets-Herzzentrum Freiburg Bad Krozingen

Bad Krozingen, , Germany

Site Status

Charite - Universitaetsmedizin Berlin

Berlin, , Germany

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Klinikum Links der Weser gGmbH

Bremen, , Germany

Site Status

Sankt Johannes Hospital Medizinische Klinik I

Dortmund, , Germany

Site Status

Sankt Johannes Hospital

Dortmund, , Germany

Site Status

Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden

Dresden, , Germany

Site Status

Georg-August-Universitaet Goettingen, Zentrum f. Innere Medizin / Kardiologie u. Pneumologie

Göttingen, , Germany

Site Status

Universitaeres Herzzentrum Hamburg

Hamburg, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

St. Vincenz Krankenhaus

Limburg, , Germany

Site Status

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

Mainz, , Germany

Site Status

Staedtisches Klinikum Muenchen GmbH Klinikum Neuperlach

Munich, , Germany

Site Status

General Hospital of Athens "Georgios Gennimatas"

Athens, , Greece

Site Status

General Hospital of Attiki KAT

Athens, , Greece

Site Status

University General Hospital of Patra

Rio Patra, , Greece

Site Status

Budai Irgalmasrendi Korhaz, Kardiologia

Budapest, , Hungary

Site Status

Petz Aladar Megyei Oktato Korhaz, Kardiologiai Osztaly

Győr, , Hungary

Site Status

Josa Andras Oktato Korhaz Egeszsegugyi Szolgaltato Nonprofit Kft., Kardiologia

Nyíregyháza, , Hungary

Site Status

Zala Megyei Korhaz, Kardiologia

Zalaegerszeg, , Hungary

Site Status

Onze Lieve Vrouwe Gasthuis, Locatie Oosterpark

Amsterdam, , Netherlands

Site Status

St. Antonius Ziekenhuis

Nieuwegein, , Netherlands

Site Status

Katedra i Klinika Kardiologii i Chorob Wewnetrznych

Bydgoszcz, , Poland

Site Status

Oddzial Kardiologiczny Wojewodzki Szpital Specjalistyczny w Olsztynie

Olsztyn, , Poland

Site Status

Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii NZOZ w Oswiecimiu G.V.M CARINT Sp. zo.o.

Oświęcim, , Poland

Site Status

Oddzial Kardiologiczny Wojewodzki Szpital Specjalistyczny We Wroclawiu

Wroclaw, , Poland

Site Status

Stredoslovensky ustav srdcovych a cievnych chorob, a.s.

Banská Bystrica, , Slovakia

Site Status

Narodny ustav srdcovych a cievnych chorob, a.s.

Bratislava, , Slovakia

Site Status

Univerzitna nemocnica Martin

Martin, , Slovakia

Site Status

Kardiocentrum Nitra, s.r.o.

Nitra, , Slovakia

Site Status

Vseobecna nemocnica Rimavska Sobota

Rimavská Sobota, , Slovakia

Site Status

Hospital Del Sas de Jerez de La Frontera

Jerez de la Frontera, Cadiz, Spain

Site Status

"Hospital Clinic i Provincial de Barcelona,Instituto Clinic del Torax

Barcelona, , Spain

Site Status

Hospital del Mar.

Barcelona, , Spain

Site Status

HOSPITAL CLINICO SAN CARLOS- Universidad Complutense de Madrid

Madrid, , Spain

Site Status

Hospital Universitario de La Paz

Madrid, , Spain

Site Status

Hospital Universitari Son Espases

Palma de Mallorca, , Spain

Site Status

Hospital General Universitario de Valencia

Valencia, , Spain

Site Status

Blackpool Victoria Hospital NHS Trust , Cardiac Research ,Lancashire Cardiac Centre

Blackpool, Lancashire, United Kingdom

Site Status

Edinburgh Royal Infirmary

Edinburgh, Lothian, United Kingdom

Site Status

Clinical Trials Unit Morriston Hospital

Swansea, Wales, United Kingdom

Site Status

City Hospital

Birmingham, , United Kingdom

Site Status

Academic cardiology Unit

Cottingham Hull, , United Kingdom

Site Status

University Hospitals Coventry and Warwickshire NHS Trust

Coventry, , United Kingdom

Site Status

Ninewells Hospital and Medical School

Dundee, , United Kingdom

Site Status

The Queens Medical Research Institute- University of Edinburgh

Edinburgh, , United Kingdom

Site Status

University Hospital of Leicester (UHL) NHS Trust

Leicester, , United Kingdom

Site Status

Clinical Trials Unit, Morriston Hospital

Swansea, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada Czechia France Germany Greece Hungary Netherlands Poland Slovakia Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Vincent J, Zannad F; REMINDER Investigators; REMINDER Investigators. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J. 2014 Sep 7;35(34):2295-302. doi: 10.1093/eurheartj/ehu164. Epub 2014 Apr 29.

Reference Type DERIVED
PMID: 24780614 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-019844-38

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

REMINDER

Identifier Type: OTHER

Identifier Source: secondary_id

A6141116

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Beta-Blocker Heart Attack Trial (BHAT)
NCT00000492 COMPLETED PHASE3